

DRAFT

SUMMARY

Digest: The Act lets a pharmacist diagnose and treat some health conditions. (Flesch Readability Score: 64.9).

Authorizes a pharmacist to assess, diagnose and treat certain health conditions. Includes the assessment, diagnosis and treatment of certain conditions in the practice of pharmacy. Authorizes a pharmacist to prescribe and dispense certain drugs and devices. Directs the Public Health and Pharmacy Formulary Advisory Committee to develop a list of health conditions that a pharmacist may assess, diagnose and treat.

Takes effect on the 91st day following adjournment sine die.

A BILL FOR AN ACT

1
2 Relating to pharmacy; creating new provisions; amending ORS 689.005,
3 689.645 and 689.649; and prescribing an effective date.

4 **Be It Enacted by the People of the State of Oregon:**

5 **SECTION 1. Section 2 of this 2025 Act is added to and made a part**
6 **of ORS chapter 689.**

7 **SECTION 2. A pharmacist may assess, diagnose and provide patient**
8 **care services, including treatment, for health conditions:**

9 (1) **That may be treated by nonprescription drugs;**

10 (2) **That are minor or generally self-limiting; or**

11 (3) **For which the Public Health and Pharmacy Formulary Advisory**
12 **Committee determines that assessment, diagnosis and treatment by a**
13 **pharmacist is in the best interest of the public.**

14 **SECTION 3. ORS 689.005, as amended by section 5, chapter 17, Oregon**
15 **Laws 2024, and section 9, chapter 70, Oregon Laws 2024, is amended to read:**
16 **689.005. As used in this chapter:**

1 (1) “Administer” means the direct application of a drug or device whether
2 by injection, inhalation, ingestion, or any other means, to the body of a pa-
3 tient or research subject by:

4 (a) A practitioner or the practitioner’s authorized agent; or

5 (b) The patient or research subject at the direction of the practitioner.

6 (2) “Approved continuing pharmacy education program” means those
7 seminars, classes, meetings, workshops and other educational programs on
8 the subject of pharmacy approved by the State Board of Pharmacy.

9 (3) “Clinical pharmacy agreement” means an agreement between a
10 pharmacist or pharmacy and a health care organization or a physician as
11 defined in ORS 677.010 or a naturopathic physician as defined in ORS 685.010
12 that permits the pharmacist to engage in the practice of clinical pharmacy
13 for the benefit of the patients of the health care organization, physician or
14 naturopathic physician.

15 (4) “Continuing pharmacy education” means:

16 (a) Professional, pharmaceutical post-graduate education in the general
17 areas of socio-economic and legal aspects of health care;

18 (b) The properties and actions of drugs and dosage forms; and

19 (c) The etiology, characteristics and therapeutics of the disease state.

20 (5) “Continuing pharmacy education unit” means the unit of measurement
21 of credits for approved continuing education courses and programs.

22 (6) “Deliver” or “delivery” means the actual, constructive or attempted
23 transfer of a drug or device other than by administration from one person
24 to another, whether or not for a consideration.

25 (7) “Device” means an instrument, apparatus, implement, machine,
26 contrivance, implant, in vitro reagent or other similar or related article, in-
27 cluding any component part or accessory, which is required under federal
28 or state law to be prescribed by a practitioner and dispensed by a
29 pharmacist.

30 (8) “Dispense” or “dispensing” means the preparation and delivery of a
31 prescription drug pursuant to a lawful order of a practitioner in a suitable

1 container appropriately labeled for subsequent administration to or use by
2 a patient or other individual entitled to receive the prescription drug.

3 (9) "Distribute" means the delivery of a drug other than by administering
4 or dispensing.

5 (10) "Drug" means:

6 (a) Articles recognized as drugs in the official United States
7 Pharmacopoeia, official National Formulary, official Homeopathic
8 Pharmacopoeia, other drug compendium or any supplement to any of them;

9 (b) Articles intended for use in the diagnosis, cure, mitigation, treatment
10 or prevention of disease in a human or other animal;

11 (c) Articles, other than food, intended to affect the structure or any
12 function of the body of humans or other animals; and

13 (d) Articles intended for use as a component of any articles specified in
14 paragraph (a), (b) or (c) of this subsection.

15 (11) "Drug order" means a written order, in a hospital or other inpatient
16 care facility, for an ultimate user of any drug or device issued and signed
17 by a practitioner, or an order transmitted by other means of communication
18 from a practitioner, that is immediately reduced to writing by a pharmacist,
19 licensed nurse or other practitioner.

20 (12) "Drug outlet" means a pharmacy, nursing home, shelter home,
21 convalescent home, extended care facility, drug abuse treatment center, penal
22 institution, hospital, family planning clinic, student health center, retail
23 store, wholesaler, manufacturer, mail-order vendor or other establishment
24 with facilities located within or out of this state that is engaged in dis-
25 pensing, delivery or distribution of drugs within this state.

26 (13) "Drug room" means a secure and lockable location within an inpa-
27 tient care facility that does not have a licensed pharmacy.

28 (14) "Electronically transmitted" or "electronic transmission" means a
29 communication sent or received through technological apparatuses, including
30 computer terminals or other equipment or mechanisms linked by telephone
31 or microwave relays, or similar apparatus having electrical, digital, mag-

1 netic, wireless, optical, electromagnetic or similar capabilities.

2 (15) “Injectable hormonal contraceptive” means a drug composed of a
3 hormone or a combination of hormones that is approved by the United States
4 Food and Drug Administration to prevent pregnancy and that a health care
5 practitioner administers to the patient by injection.

6 (16) “Institutional drug outlet” means hospitals and inpatient care facili-
7 ties where medications are dispensed to another health care professional for
8 administration to patients served by the hospitals or facilities.

9 (17) “Intern” means a person who is enrolled in or has completed a course
10 of study at a school or college of pharmacy approved by the board and who
11 is licensed with the board as an intern.

12 (18) “Internship” means a professional experiential program approved by
13 the board under the supervision of a licensed pharmacist registered with the
14 board as a preceptor.

15 (19) “Labeling” means the process of preparing and affixing of a label to
16 any drug container exclusive, however, of the labeling by a manufacturer,
17 packer or distributor of a nonprescription drug or commercially packaged
18 legend drug or device.

19 (20) “Manufacture” means the production, preparation, propagation, com-
20 pounding, conversion or processing of a device or a drug, either directly or
21 indirectly by extraction from substances of natural origin or independently
22 by means of chemical synthesis or by a combination of extraction and
23 chemical synthesis and includes any packaging or repackaging of the sub-
24 stances or labeling or relabeling of its container, except that this term does
25 not include the preparation or compounding of a drug by an individual for
26 their own use or the preparation, compounding, packaging or labeling of a
27 drug:

28 (a) By a practitioner as an incident to administering or dispensing of a
29 drug in the course of professional practice; or

30 (b) By a practitioner or by the practitioner’s authorization under super-
31 vision of the practitioner for the purpose of or as an incident to research,

1 teaching or chemical analysis and not for sale.

2 (21) “Manufacturer” means a person engaged in the manufacture of drugs.

3 (22) “Nonprescription drug outlet” means a business or other establish-
4 ment that is open to the general public for the sale or nonprofit distribution
5 of nonprescription drugs and is registered under ORS 689.305.

6 (23) “Nonprescription drugs” means drugs that may be sold without a
7 prescription and that are prepackaged for use by the consumer and labeled
8 in accordance with the requirements of the statutes and regulations of this
9 state and the federal government.

10 (24) “Person” means an individual, corporation, partnership, association
11 or other legal entity.

12 (25) “Pharmacist” means an individual licensed by this state to engage in
13 the practice of pharmacy or to engage in the practice of clinical pharmacy.

14 (26) “Pharmacy” means a place that meets the requirements of rules of
15 the board, is licensed and approved by the board where the practice of
16 pharmacy may lawfully occur and includes apothecaries, drug stores,
17 dispensaries, hospital outpatient pharmacies, pharmacy departments and
18 prescription laboratories but does not include a place used by a manufacturer
19 or wholesaler.

20 (27) “Pharmacy technician” means a person licensed by the board who
21 assists in the practice of pharmacy pursuant to rules of the board.

22 (28) “Practice of clinical pharmacy” means:

23 (a) The health science discipline in which, in conjunction with the
24 patient’s other practitioners, a pharmacist provides patient care to optimize
25 medication therapy and to promote disease prevention and the patient’s
26 health and wellness;

27 (b) The provision of patient care services, including but not limited to
28 post-diagnostic disease state management services; and

29 (c) The practice of pharmacy by a pharmacist pursuant to a clinical
30 pharmacy agreement.

31 (29) “Practice of pharmacy” means:

- 1 (a) The interpretation and evaluation of prescription orders;
- 2 (b) The compounding, dispensing and labeling of drugs and devices, except
3 labeling by a manufacturer, packer or distributor of nonprescription drugs
4 and commercially packaged legend drugs and devices;
- 5 (c) The prescribing and administering of vaccines and immunizations and
6 the providing of patient care services pursuant to ORS 689.645;
- 7 (d) The administering of drugs and devices to the extent permitted under
8 ORS 689.655;
- 9 (e) The participation in drug selection and drug utilization reviews;
- 10 (f) The proper and safe storage of drugs and devices and the maintenance
11 of proper records regarding the safe storage of drugs and devices;
- 12 (g) The responsibility for advising, where necessary or where regulated,
13 of therapeutic values, content, hazards and use of drugs and devices;
- 14 (h) The monitoring of therapeutic response or adverse effect to drug
15 therapy;
- 16 (i) The optimizing of drug therapy through the practice of clinical phar-
17 macy;
- 18 (j) Patient care services, including medication therapy management and
19 comprehensive medication review;
- 20 (k) The offering or performing of those acts, services, operations or
21 transactions necessary in the conduct, operation, management and control
22 of pharmacy;
- 23 (L) The prescribing and administering of injectable hormonal
24 contraceptives and the prescribing and dispensing of self-administered
25 hormonal contraceptives pursuant to ORS 689.689;
- 26 (m) The prescribing and dispensing of emergency refills of insulin and
27 associated insulin-related devices and supplies pursuant to ORS 689.696;
- 28 (n) The prescribing, dispensing and administering of preexposure
29 prophylactic antiretroviral therapies and post-exposure prophylactic
30 antiretroviral therapies, pursuant to ORS 689.704 and rules adopted by the
31 board under ORS 689.645 and 689.704;

1 (o) The delegation of tasks to other health care providers who are ap-
2 propriately trained and authorized to perform the delegated tasks;

3 (p) The prescribing and dispensing of early refills of medication for the
4 treatment of opioid use disorder pursuant to section 7, chapter 70, Oregon
5 Laws 2024; [and]

6 (q) The testing for severe acute respiratory syndrome coronavirus 2
7 (SARS-CoV-2) and the prescribing, dispensing and administering of treatment
8 for SARS-CoV-2 pursuant to section 4, chapter 17, Oregon Laws 2024, and
9 rules adopted by the board pursuant to section 4, chapter 17, Oregon Laws
10 2024[.]; **and**

11 **(r) The assessment, diagnosis and provision of patient care services**
12 **of health conditions pursuant to section 2 of this 2025 Act.**

13 (30) “Practitioner” means a person licensed and operating within the
14 scope of such license to prescribe, dispense, conduct research with respect
15 to or administer drugs in the course of professional practice or research:

16 (a) In this state; or

17 (b) In another state or territory of the United States if the person does
18 not reside in Oregon and is registered under the federal Controlled Sub-
19 stances Act.

20 (31) “Preceptor” means a pharmacist or a person licensed by the board to
21 supervise the internship training of a licensed intern.

22 (32) “Prescription drug” or “legend drug” means a drug that is:

23 (a) Required by federal law, prior to being dispensed or delivered, to be
24 labeled with either of the following statements:

25 (A) “Caution: Federal law prohibits dispensing without prescription”; or

26 (B) “Caution: Federal law restricts this drug to use by or on the order
27 of a licensed veterinarian”; or

28 (b) Required by any applicable federal or state law or regulation to be
29 dispensed on prescription only or is restricted to use by practitioners only.

30 (33) “Prescription” or “prescription drug order” means a written, oral or
31 electronically transmitted direction, given by a practitioner authorized to

1 prescribe drugs, for the preparation and use of a drug. When the context
2 requires, “prescription” also means the drug prepared under such written,
3 oral or electronically transmitted direction.

4 (34) “Retail drug outlet” means a place used for the conduct of the retail
5 sale, administering or dispensing or compounding of drugs or chemicals or
6 for the administering or dispensing of prescriptions and licensed by the board
7 as a place where the practice of pharmacy may lawfully occur.

8 (35) “Self-administered hormonal contraceptive” means a drug composed
9 of a hormone or a combination of hormones that is approved by the United
10 States Food and Drug Administration to prevent pregnancy and that the
11 patient to whom the drug is prescribed may administer to oneself. “Self-
12 administered hormonal contraceptive” includes, but is not limited to,
13 hormonal contraceptive patches and hormonal contraceptive pills.

14 (36) “Third-party logistics provider” means an entity that:

15 (a) Provides or coordinates warehousing of, or other logistics services for,
16 a product in interstate commerce on behalf of a manufacturer, wholesale
17 distributor or dispenser of the product; and

18 (b) Does not take ownership of, or have responsibility to direct the sale
19 or disposition of, the product.

20 (37) “Unit dose” means a sealed single-unit container so designed that the
21 contents are administered to the patient as a single dose, direct from the
22 container. Each unit dose container must bear a separate label, be labeled
23 with the name and strength of the medication, the name of the manufacturer
24 or distributor, an identifying lot number and, if applicable, the expiration
25 date of the medication.

26 (38) “Wholesale distributor drug outlet” means a person, other than a
27 manufacturer, manufacturer’s colicensed partner, third-party logistics pro-
28 vider or repackager, as defined in 21 U.S.C. 360eee(16), that is engaged in
29 wholesale distribution, as defined in 21 U.S.C. 353(e)(4).

30 **SECTION 4.** ORS 689.005, as amended by sections 5 and 6, chapter 17,
31 Oregon Laws 2024, and section 9, chapter 70, Oregon Laws 2024, is amended

1 to read:

2 689.005. As used in this chapter:

3 (1) "Administer" means the direct application of a drug or device whether
4 by injection, inhalation, ingestion, or any other means, to the body of a pa-
5 tient or research subject by:

6 (a) A practitioner or the practitioner's authorized agent; or

7 (b) The patient or research subject at the direction of the practitioner.

8 (2) "Approved continuing pharmacy education program" means those
9 seminars, classes, meetings, workshops and other educational programs on
10 the subject of pharmacy approved by the State Board of Pharmacy.

11 (3) "Clinical pharmacy agreement" means an agreement between a
12 pharmacist or pharmacy and a health care organization or a physician as
13 defined in ORS 677.010 or a naturopathic physician as defined in ORS 685.010
14 that permits the pharmacist to engage in the practice of clinical pharmacy
15 for the benefit of the patients of the health care organization, physician or
16 naturopathic physician.

17 (4) "Continuing pharmacy education" means:

18 (a) Professional, pharmaceutical post-graduate education in the general
19 areas of socio-economic and legal aspects of health care;

20 (b) The properties and actions of drugs and dosage forms; and

21 (c) The etiology, characteristics and therapeutics of the disease state.

22 (5) "Continuing pharmacy education unit" means the unit of measurement
23 of credits for approved continuing education courses and programs.

24 (6) "Deliver" or "delivery" means the actual, constructive or attempted
25 transfer of a drug or device other than by administration from one person
26 to another, whether or not for a consideration.

27 (7) "Device" means an instrument, apparatus, implement, machine,
28 contrivance, implant, in vitro reagent or other similar or related article, in-
29 cluding any component part or accessory, which is required under federal
30 or state law to be prescribed by a practitioner and dispensed by a
31 pharmacist.

1 (8) “Dispense” or “dispensing” means the preparation and delivery of a
2 prescription drug pursuant to a lawful order of a practitioner in a suitable
3 container appropriately labeled for subsequent administration to or use by
4 a patient or other individual entitled to receive the prescription drug.

5 (9) “Distribute” means the delivery of a drug other than by administering
6 or dispensing.

7 (10) “Drug” means:

8 (a) Articles recognized as drugs in the official United States
9 Pharmacopoeia, official National Formulary, official Homeopathic
10 Pharmacopoeia, other drug compendium or any supplement to any of them;

11 (b) Articles intended for use in the diagnosis, cure, mitigation, treatment
12 or prevention of disease in a human or other animal;

13 (c) Articles, other than food, intended to affect the structure or any
14 function of the body of humans or other animals; and

15 (d) Articles intended for use as a component of any articles specified in
16 paragraph (a), (b) or (c) of this subsection.

17 (11) “Drug order” means a written order, in a hospital or other inpatient
18 care facility, for an ultimate user of any drug or device issued and signed
19 by a practitioner, or an order transmitted by other means of communication
20 from a practitioner, that is immediately reduced to writing by a pharmacist,
21 licensed nurse or other practitioner.

22 (12) “Drug outlet” means a pharmacy, nursing home, shelter home,
23 convalescent home, extended care facility, drug abuse treatment center, penal
24 institution, hospital, family planning clinic, student health center, retail
25 store, wholesaler, manufacturer, mail-order vendor or other establishment
26 with facilities located within or out of this state that is engaged in dis-
27 pensing, delivery or distribution of drugs within this state.

28 (13) “Drug room” means a secure and lockable location within an inpa-
29 tient care facility that does not have a licensed pharmacy.

30 (14) “Electronically transmitted” or “electronic transmission” means a
31 communication sent or received through technological apparatuses, including

1 computer terminals or other equipment or mechanisms linked by telephone
2 or microwave relays, or similar apparatus having electrical, digital, mag-
3 netic, wireless, optical, electromagnetic or similar capabilities.

4 (15) “Injectable hormonal contraceptive” means a drug composed of a
5 hormone or a combination of hormones that is approved by the United States
6 Food and Drug Administration to prevent pregnancy and that a health care
7 practitioner administers to the patient by injection.

8 (16) “Institutional drug outlet” means hospitals and inpatient care facili-
9 ties where medications are dispensed to another health care professional for
10 administration to patients served by the hospitals or facilities.

11 (17) “Intern” means a person who is enrolled in or has completed a course
12 of study at a school or college of pharmacy approved by the board and who
13 is licensed with the board as an intern.

14 (18) “Internship” means a professional experiential program approved by
15 the board under the supervision of a licensed pharmacist registered with the
16 board as a preceptor.

17 (19) “Labeling” means the process of preparing and affixing of a label to
18 any drug container exclusive, however, of the labeling by a manufacturer,
19 packer or distributor of a nonprescription drug or commercially packaged
20 legend drug or device.

21 (20) “Manufacture” means the production, preparation, propagation, com-
22 pounding, conversion or processing of a device or a drug, either directly or
23 indirectly by extraction from substances of natural origin or independently
24 by means of chemical synthesis or by a combination of extraction and
25 chemical synthesis and includes any packaging or repackaging of the sub-
26 stances or labeling or relabeling of its container, except that this term does
27 not include the preparation or compounding of a drug by an individual for
28 their own use or the preparation, compounding, packaging or labeling of a
29 drug:

30 (a) By a practitioner as an incident to administering or dispensing of a
31 drug in the course of professional practice; or

1 (b) By a practitioner or by the practitioner's authorization under super-
2 vision of the practitioner for the purpose of or as an incident to research,
3 teaching or chemical analysis and not for sale.

4 (21) "Manufacturer" means a person engaged in the manufacture of drugs.

5 (22) "Nonprescription drug outlet" means a business or other establish-
6 ment that is open to the general public for the sale or nonprofit distribution
7 of nonprescription drugs and is registered under ORS 689.305.

8 (23) "Nonprescription drugs" means drugs that may be sold without a
9 prescription and that are prepackaged for use by the consumer and labeled
10 in accordance with the requirements of the statutes and regulations of this
11 state and the federal government.

12 (24) "Person" means an individual, corporation, partnership, association
13 or other legal entity.

14 (25) "Pharmacist" means an individual licensed by this state to engage in
15 the practice of pharmacy or to engage in the practice of clinical pharmacy.

16 (26) "Pharmacy" means a place that meets the requirements of rules of
17 the board, is licensed and approved by the board where the practice of
18 pharmacy may lawfully occur and includes apothecaries, drug stores,
19 dispensaries, hospital outpatient pharmacies, pharmacy departments and
20 prescription laboratories but does not include a place used by a manufacturer
21 or wholesaler.

22 (27) "Pharmacy technician" means a person licensed by the board who
23 assists in the practice of pharmacy pursuant to rules of the board.

24 (28) "Practice of clinical pharmacy" means:

25 (a) The health science discipline in which, in conjunction with the
26 patient's other practitioners, a pharmacist provides patient care to optimize
27 medication therapy and to promote disease prevention and the patient's
28 health and wellness;

29 (b) The provision of patient care services, including but not limited to
30 post-diagnostic disease state management services; and

31 (c) The practice of pharmacy by a pharmacist pursuant to a clinical

1 pharmacy agreement.

2 (29) "Practice of pharmacy" means:

3 (a) The interpretation and evaluation of prescription orders;

4 (b) The compounding, dispensing and labeling of drugs and devices, except
5 labeling by a manufacturer, packer or distributor of nonprescription drugs
6 and commercially packaged legend drugs and devices;

7 (c) The prescribing and administering of vaccines and immunizations and
8 the providing of patient care services pursuant to ORS 689.645;

9 (d) The administering of drugs and devices to the extent permitted under
10 ORS 689.655;

11 (e) The participation in drug selection and drug utilization reviews;

12 (f) The proper and safe storage of drugs and devices and the maintenance
13 of proper records regarding the safe storage of drugs and devices;

14 (g) The responsibility for advising, where necessary or where regulated,
15 of therapeutic values, content, hazards and use of drugs and devices;

16 (h) The monitoring of therapeutic response or adverse effect to drug
17 therapy;

18 (i) The optimizing of drug therapy through the practice of clinical phar-
19 macy;

20 (j) Patient care services, including medication therapy management and
21 comprehensive medication review;

22 (k) The offering or performing of those acts, services, operations or
23 transactions necessary in the conduct, operation, management and control
24 of pharmacy;

25 (L) The prescribing and administering of injectable hormonal
26 contraceptives and the prescribing and dispensing of self-administered
27 hormonal contraceptives pursuant to ORS 689.689;

28 (m) The prescribing and dispensing of emergency refills of insulin and
29 associated insulin-related devices and supplies pursuant to ORS 689.696;

30 (n) The prescribing, dispensing and administering of preexposure
31 prophylactic antiretroviral therapies and post-exposure prophylactic

1 antiretroviral therapies, pursuant to ORS 689.704 and rules adopted by the
2 board under ORS 689.645 and 689.704;

3 (o) The delegation of tasks to other health care providers who are ap-
4 propriately trained and authorized to perform the delegated tasks; *[and]*

5 (p) The prescribing and dispensing of early refills of medication for the
6 treatment of opioid use disorder pursuant to section 7, chapter 70, Oregon
7 Laws 2024[.]; **and**

8 **(q) The assessment, diagnosis and provision of patient care services**
9 **of health conditions pursuant to section 2 of this 2025 Act.**

10 (30) “Practitioner” means a person licensed and operating within the
11 scope of such license to prescribe, dispense, conduct research with respect
12 to or administer drugs in the course of professional practice or research:

13 (a) In this state; or

14 (b) In another state or territory of the United States if the person does
15 not reside in Oregon and is registered under the federal Controlled Sub-
16 stances Act.

17 (31) “Preceptor” means a pharmacist or a person licensed by the board to
18 supervise the internship training of a licensed intern.

19 (32) “Prescription drug” or “legend drug” means a drug that is:

20 (a) Required by federal law, prior to being dispensed or delivered, to be
21 labeled with either of the following statements:

22 (A) “Caution: Federal law prohibits dispensing without prescription”; or

23 (B) “Caution: Federal law restricts this drug to use by or on the order
24 of a licensed veterinarian”; or

25 (b) Required by any applicable federal or state law or regulation to be
26 dispensed on prescription only or is restricted to use by practitioners only.

27 (33) “Prescription” or “prescription drug order” means a written, oral or
28 electronically transmitted direction, given by a practitioner authorized to
29 prescribe drugs, for the preparation and use of a drug. When the context
30 requires, “prescription” also means the drug prepared under such written,
31 oral or electronically transmitted direction.

1 (34) “Retail drug outlet” means a place used for the conduct of the retail
2 sale, administering or dispensing or compounding of drugs or chemicals or
3 for the administering or dispensing of prescriptions and licensed by the board
4 as a place where the practice of pharmacy may lawfully occur.

5 (35) “Self-administered hormonal contraceptive” means a drug composed
6 of a hormone or a combination of hormones that is approved by the United
7 States Food and Drug Administration to prevent pregnancy and that the
8 patient to whom the drug is prescribed may administer to oneself. “Self-
9 administered hormonal contraceptive” includes, but is not limited to,
10 hormonal contraceptive patches and hormonal contraceptive pills.

11 (36) “Third-party logistics provider” means an entity that:

12 (a) Provides or coordinates warehousing of, or other logistics services for,
13 a product in interstate commerce on behalf of a manufacturer, wholesale
14 distributor or dispenser of the product; and

15 (b) Does not take ownership of, or have responsibility to direct the sale
16 or disposition of, the product.

17 (37) “Unit dose” means a sealed single-unit container so designed that the
18 contents are administered to the patient as a single dose, direct from the
19 container. Each unit dose container must bear a separate label, be labeled
20 with the name and strength of the medication, the name of the manufacturer
21 or distributor, an identifying lot number and, if applicable, the expiration
22 date of the medication.

23 (38) “Wholesale distributor drug outlet” means a person, other than a
24 manufacturer, manufacturer’s colicensed partner, third-party logistics pro-
25 vider or repackager, as defined in 21 U.S.C. 360eee(16), that is engaged in
26 wholesale distribution, as defined in 21 U.S.C. 353(e)(4).

27 **SECTION 5.** ORS 689.645 is amended to read:

28 689.645. (1) In accordance with rules adopted by the State Board of
29 Pharmacy under ORS 689.205:

30 (a) A pharmacist, or a pharmacy technician under the supervision of a
31 pharmacist, may administer vaccines:

1 (A) To persons who are seven years of age or older;

2 (B) If authorized by the Governor or the Director of the Oregon Depart-
3 ment of Emergency Management under ORS 433.441 or the Public Health
4 Director under ORS 433.443 or 433.444, to a person three years of age or
5 older; or

6 (C) To persons who are six months of age or older if the vaccine admin-
7 istered is an influenza vaccine.

8 (b) A pharmacist may, pursuant to a statewide drug therapy management
9 protocol developed by the Public Health and Pharmacy Formulary Advisory
10 Committee convened under ORS 689.649 and adopted by rule of the board,
11 provide approved patient care services including smoking cessation therapy
12 and travel health services.

13 (c) A pharmacist may, using a form prescribed by the board, submit a
14 concept for the development of a protocol, other than the protocols
15 pharmacists may establish under subsection (5) of this section, to the com-
16 mittee for consideration by the committee and recommendation to the board
17 for adoption by rule of the board.

18 (d) A pharmacist may prescribe and dispense a drug or device included
19 on the formulary established under subsection (6) of this section if the pre-
20 scription and dispensation is:

21 (A) Pursuant to a diagnosis by a health care practitioner who has
22 prescriptive authority and is qualified to make the diagnosis[.]; **or**

23 **(B) Made within the pharmacist's scope of practice.**

24 (2) The board may adopt rules allowing a pharmacist to prescribe vac-
25 cines, provide patient care services and submit protocol concepts under sub-
26 section (1) of this section. The rules related to the prescription of vaccines
27 may be only as broad as necessary to enable pharmacists to enroll and par-
28 ticipate in the Vaccines for Children Program administered by the Centers
29 for Disease Control and Prevention.

30 (3) The board is authorized to issue, to pharmacists and pharmacy tech-
31 nicians who have completed training accredited by the Centers for Disease

1 Control and Prevention, the Accreditation Council for Pharmacy Education
2 or a similar health authority or professional body, certificates of special
3 competency in the prescription or administration of vaccines.

4 (4) The board shall adopt rules relating to the reporting of the pre-
5 scription and administration of vaccines to a patient's primary health care
6 provider and to the Oregon Health Authority.

7 (5) The board shall adopt rules requiring pharmacists to establish proto-
8 cols for the prescription and administration of vaccines and the provision
9 of patient care services under subsection (1) of this section.

10 (6)(a) The board shall establish by rule a formulary of drugs and devices,
11 as recommended by the committee, that a pharmacist may prescribe and
12 dispense to a patient [*pursuant to a diagnosis by a health care practitioner*
13 *who has prescriptive authority and who is qualified to make the diagnosis*]
14 **under subsection (1)(d) of this section.**

15 (b) The formulary may include post-diagnostic drugs and devices such as
16 diabetic testing supplies, emergency refills of insulin, albuterol inhalers,
17 epinephrine autoinjectors, smoking cessation aids, discharge medications for
18 transitions of care, rapid strep tests and spacers.

19 **SECTION 6.** ORS 689.649 is amended to read:

20 689.649. (1) The State Board of Pharmacy shall convene a Public Health
21 and Pharmacy Formulary Advisory Committee consisting of seven members,
22 appointed by the Governor, for the purpose of advising the board in
23 promulgating rules under ORS 689.645. The committee shall consist of:

24 (a) Two physicians licensed to practice medicine under ORS 677.100 to
25 677.228;

26 (b) Two advanced practice registered nurses who have prescriptive au-
27 thority and who are licensed by the Oregon State Board of Nursing; and

28 (c) Three pharmacists licensed by the State Board of Pharmacy, at least
29 one of whom is employed as a community pharmacist and one of whom is
30 employed as a health system pharmacist.

31 (2) The Oregon Medical Board, the Oregon State Board of Nursing and

1 the State Board of Pharmacy may each submit to the Governor a list of up
2 to three names of individuals to be considered for membership for each of
3 the vacancies required to be filled by licensees of each board.

4 (3) The term of each member of the committee is two years. A member
5 whose term has expired shall continue to serve until a successor is ap-
6 pointed. If a vacancy occurs, a person who is a representative of the same
7 state agency as the departing member shall serve for the remainder of the
8 term.

9 (4) The committee shall elect one of its members to serve as chairperson.

10 (5) Members of the committee are entitled to compensation and expenses
11 as provided in ORS 292.495, to be paid by the State Board of Pharmacy.

12 (6) A member of the committee who fails to attend two consecutive
13 meetings of the committee shall be removed from the committee unless the
14 failure to attend was because of a serious health condition of the member
15 or a family member of the member.

16 (7) The committee shall recommend to the State Board of Pharmacy for
17 adoption by rule of the board a formulary of drugs and devices that a
18 pharmacist may prescribe and dispense to a patient pursuant to a diagnosis
19 by a health care practitioner qualified to make the diagnosis. The committee
20 shall periodically review the formulary and recommend the revisions to the
21 board for adoption by rule.

22 (8) A pharmacist may request that the committee add a drug or device to
23 the formulary by submitting to the committee a request form prescribed by
24 the State Board of Pharmacy. The addition to the formulary of a drug or
25 device under this subsection shall be considered a revision to the formulary
26 that the committee may recommend to the board for adoption by rule.

27 **(9) The committee may develop and maintain a list of health con-**
28 **ditions that the committee determines to be within the scope of prac-**
29 **tice of a pharmacist to assess, diagnose and treat. The conditions**
30 **included on the list under this subsection must be minor or generally**
31 **self-limiting, or within the best interests of the public to be assessed,**

1 **diagnosed and treated by a pharmacist. The committee may review**
2 **and revise the list as the committee determines necessary and shall**
3 **make the list publicly available.**

4 **SECTION 7. (1) Section 2 of this 2025 Act and the amendments to**
5 **ORS 689.005, 689.645 and 689.649 by sections 3 to 6 of this 2025 Act be-**
6 **come operative on January 1, 2026.**

7 **(2) The State Board of Pharmacy and the Public Health and Phar-**
8 **macy Formulary Advisory Committee may take any action before the**
9 **operative date specified in subsection (1) of this section that is neces-**
10 **sary to enable the board and the committee to exercise, on and after**
11 **the operative date specified in subsection (1) of this section, all of the**
12 **duties, functions and powers conferred on the board and the commit-**
13 **tee by section 2 of this 2025 Act and the amendments to ORS 689.005,**
14 **689.645 and 689.649 by sections 3 to 6 of this 2025 Act.**

15 **SECTION 8. This 2025 Act takes effect on the 91st day after the date**
16 **on which the 2025 regular session of the Eighty-third Legislative As-**
17 **sembly adjourns sine die.**

18
